Citations

Showing 10 of 108083 citations.

Development and application of a computable genotype model in the GA4GH Variation Representation Specification
Goar, Wesley , Babb, Lawrence , Cline, Melissa , Kuzma, Kori , Lee, Jennifer , Nelson, Tristan , Smith, Anastasia , Stahl, Kathryn , Bratulin, Anastasia L. , Babb, Lawrence , Chamala, Srikar , Freimuth, Robert R. , Hart, Reece K. , Prlić, Andreas , Riehle, Kevin P. , Yates, Andrew , Rehm, Heidi L. , Wagner, Alex H.

Mayo Clinic

Biocomputing 2023 | November 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: 383-394

10.1142/9789811270611_0035 Get It

Risk of Arthroplasty in Patients with Subchondral Insufficiency Fractures of the Knee: A Matched Study of the Implantable Shock Absorber using a Validated Predictive Model
Pareek, Ayoosh , Parkes, Chad W. , Słynarski, Konrad , Śmigıelski, Robert , Merwe, Willem van der, Walawski, Jacek , Krych, Aaron J.

Mayo Clinic

The Journal of Knee Surgery | November 24, 2022 | Volume: 37 | Issue: 01 | Pages: 073-078

10.1055/a-1984-9980 | PMID 36417980 Get It

AbstractSubchondral insufficiency fractures of the knee (SIFK) can result in high rates of osteoarthritis and arthroplasty. The implantable shock absorber (ISA) implant is a titanium and polycarbonate urethane device which reduces the load on the medial compartment of the knee by acting as an extra-articular load absorber while preserving the joint itself. The purpose of this study was to evaluate whether partially unloading the knee with the ISA altered the likelihood of progression to arthroplasty utilizing a validated predictive risk model (SIFK score). A retrospective case-control (2:1) study was performed on patients with SIFK without any previous surgery and on those implanted with the ISA with the primary outcome being progression to arthroplasty compared with nonoperative treatment at 2 years. Baseline and final radiographs, as well as magnetic resonance imagings, were reviewed for the evaluation of meniscus or ligament injuries, insufficiency fractures, and subchondral edema. Patients from a prospective study were matched using the exact SIFK Score, a validated predictive score for progression to arthroplasty in patients with SIFK, to those who received the ISA implant. Kaplan–Meier analysis was conducted to assess survival. A total of 57 patients (38 controls:19 ISA) with a mean age of 60.6 years and 54% female were included. The SIFK score was matched exactly between cases and controls for all patients. The 2-year survival rate of 100% for the ISA group was significantly higher than the corresponding rate of 61% for the control group (p < 0.01). In ISA, 0% of the patients converted to arthroplasty at 2 years, and 5% (one patient) had hardware removal at 1 year. When stratified by risk, the ISA group did not have a significantly higher survival compared with low-risk (p = 0.3) or medium-risk (p = 0.2) controls, though it had a significantly higher survival for high-risk groups at 2 years (100 vs. 15%, p < 0.01). SIFK of the medial knee can lead to significant functional limitation and high rates of conversion to arthroplasty. Implants such as the ISA have the potential to alter the progression to arthroplasty in these patients, especially those at high risk.
Challenging Cases in Neuro-Oncology
Lukas, Rimas V. , Mrugała, Maciej M. , Chandler, James P. , Lesniak, Maciej S.

Mayo Clinic

Seminars in Neurology | November 24, 2022 | Volume: 42 | Issue: 06 | Pages: 752-757

10.1055/a-1985-7157 | PMID 36417993 Get It

AbstractNeuro-oncology encompasses a broad field focusing on an array of neoplasms, many of which can mimic several diseases. Neurologists will often be involved in the initial diagnostic evaluation and management of these patients. Their insight is central to optimizing the diagnostic yield and providing high-level clinical care. Several neuro-oncologic cases are reviewed with a goal of increasing the understanding of these diseases in a clinically relevant manner and providing updates on the contemporary thinking in the subspecialty.
Challenging Myelopathy Cases
Zalewski, Nicholas L. , Kumar, Neeraj , Mustafa, Rafid , Flanagan, E P , Flanagan, Eoin P.

Mayo Clinic

Seminars in Neurology | November 24, 2022 | Volume: 42 | Issue: 06 | Pages: 723-734

10.1055/a-1985-0124 | PMID 36417994 Get It

AbstractMisdiagnosis of myelopathies is common and can lead to irreversible disability when diagnosis- and disease-specific treatments are delayed. Therefore, quickly determining the etiology of myelopathy is crucial. Clinical evaluation and MRI spine are paramount in establishing the correct diagnosis and subsequently an appropriate treatment plan. Herein, we review an approach to myelopathy diagnosis focused on the time course of neurologic symptom progression and neuroimaging pearls, and apply them to a variety of inflammatory, structural, and vascular myelopathy cases.
Septic Pulmonary Embolism: A Contemporary Profile
Valerio, Luca , Baddour, Larry M.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | November 24, 2022 | Volume: 49 | Issue: 08 | Pages: 840-847

10.1055/s-0042-1758742 | PMID 36417928 Get It

AbstractSeptic pulmonary embolism (SPE) is a rare clinical entity that is distinct from the classic and more common non-septic thrombotic pulmonary embolism. SPE should be suspected in patients with a systemic acute inflammatory reaction or sepsis who develop signs and symptoms of pulmonary involvement. The diagnosis of SPE depends on the specific radiologic finding of multiple, peripheral, nodular, possibly cavitated lesions. SPE should prompt an immediate search for the primary source of infection; typically, right-sided infective endocarditis, cardiac implantable electronic devices, and septic thrombophlebitis as a complication of bone, skin, and soft tissue infection including Lemierre's syndrome, indwelling catheters, or direct inoculation via injection drug use. Invasive treatment of the infection source may be necessary; in thrombophlebitis, the efficacy and safety of anticoagulation remain undefined. Blood cultures may be negative, particularly among patients with recent antibiotic exposure, and broad-spectrum antimicrobial therapy should be considered. The in-hospital mortality of SPE ranges up to 20% in published case series. While trends in the incidence of SPE are unknown, the opioid epidemic, the growing use of cardiac implantable electronic devices worldwide, and the reported increase in cases of septic thrombophlebitis may be leading to an escalation in SPE cases. We provide a contemporary profile of SPE and propose a clinical management algorithm in patients with suspected or confirmed SPE.
Pulsatile Pressure Delivery of Continuous-Flow Left Ventricular Assist Devices Is Markedly Reduced Relative to Heart Failure Patients
Rosenbaum, Andrew , Rossman, Timothy, Reddy, Yogesh N.V. , Villavicencio, Mauricio A. , Stulak, John M., Spencer, Philip J. , Kushwaha, Sudhir S. , Behfar, Atta , Rosenbaum, Andrew N , Rossman, Timothy L, Nishimura, Rick , Behfar, Atta , Kushwaha, Sudhir

Mayo Clinic

ASAIO Journal | November 23, 2022 | Volume: 69 | Issue: 5 | Pages: 445-450

10.1097/mat.0000000000001859 | PMID 36417497 Get It

Although continuous-flow left ventricular assist devices (CF-LVADs) provide an augmentation in systemic perfusion, there is a scarcity of in vivo data regarding systemic pulsatility on support. Patients supported on CF-LVAD therapy (n = 71) who underwent combined left/right catheterization ramp study were included. Aortic pulsatility was defined by the pulsatile power index (PPI), which was also calculated in a cohort of high-output heart failure (HOHF, n = 66) and standard HF cohort (n = 44). PPI was drastically lower in CF-LVAD–supported patients with median PPI of 0.006 (interquartile range [IQR], 0.002–0.012) compared with PPI in the HF population at 0.09 (IQR, 0.06–0.17) or HOHF population at 0.25 (IQR, 0.13–0.37; p < 0.0001 among groups). With speed augmentation during ramp, PPI values fell quickly in patients with higher PPI at baseline. PPI correlated poorly with left ventricular ejection fraction (LVEF) in all groups. In CF-LVAD patients, there was a stronger correlation with LV dP/dt (r = 0.41; p = 0.001) than LVEF (r = 0.21; p = 0.08; p int < 0.001). CF-LVAD support is associated with a dramatic reduction in arterial pulsatility as measured by PPI relative to HOHF and HF cohorts and decreases with speed. Further work is needed to determine the applicability to the next generation of device therapy.
Ocular manifestations of ANCA-associated vasculitis
Junek, Mats , Zhao, Lily, Garner, Stephanie , Cuthbertson, David , Pagnoux, Christian , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Rhee, Rennie L. , Sreih, Antoine G. , Junek, Mats L , Warrington, Kenneth J , Moreland, Larry W , Pagnoux, Christian , Monach, Paul A. , Seo, Philip , Specks, Ulrich , Warrington, Kenneth J. , Wechsler, Michael E , Merkel, Peter A. , Khalidi, Nader

Mayo Clinic

Rheumatology | November 23, 2022 | Volume: 62 | Issue: 7 | Pages: 2517-2524

10.1093/rheumatology/keac663 | PMID 36440847 Get It

Abstract Objectives ANCA-associated vasculitis (AAV) is a group of multisystem diseases that can have several ocular manifestations. There are published data on ocular manifestations of granulomatosis with polyangiitis (GPA), but few for eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyangiitis (MPA). There is little information concerning chronicity, complications, and association with other cranial manifestations of AAV. Methods This study retrospectively analysed longitudinal multicentre cohorts of individuals with AAV followed between 2006 and 2022. Data included diagnosis, demographics, cranial manifestations of disease, presence of manifestations at onset of disease and/or follow-up, and ocular complications of disease. Univariate and multivariable logistic regression analysis assessed associations across disease manifestations. Results Data from 1441 patients were analysed, including 395 with EGPA, 876 with GPA, and 170 with MPA. Ocular manifestations were seen within 23.1% of patients: 39 (9.9%) with EGPA, 287 (32.7%) with GPA, and 12 (7.1%) with MPA at any time in the disease course. There were more ocular manifestations at onset (n = 224) than during follow-up (n = 120). The most common disease-related manifestations were conjunctivitis/episcleritis and scleritis. In multivariable analysis, dacryocystitis, lacrimal duct obstruction, and retro-orbital disease were associated with sinonasal manifestations of GPA; ocular manifestations were associated with hearing loss in MPA. The most common ocular complications and/or damage seen were cataracts (n = 168) and visual impairment (n = 195). Conclusion Ocular manifestations occur in all forms of AAV, especially in GPA. Clinicians should be mindful of the wide spectrum of ocular disease in AAV, caused by active vasculitis, disease-associated damage, and toxicities of therapy.
Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials
Islam, Mahnoor, Ikram, Waleed, Naqvi, Syed Arsalan Ahmed , Riaz, Anum, Ravi, Praful , Odedina, Folakemi T., Duma, Narjust , Kehl, Kenneth L. , Kamran, Sophia C. , Bryce, Alan H. , Singh, Parminder , Riaz, Irbaz Bin , Murad, Mohammad Hassan, Bryce, Alan Haruo, Bryce, Alan H , Singh, Parminder , Maqsood, Hamza , Saleem, Yusra, Wang, Zhen , Hussain, Syed A. , Warner, Jeremy L. , Singh, Parminder Pal , Murad, M. Hassan , Landman, Adam , Van Allen, Eliezer M

Mayo Clinic

JAMA Oncology | November 23, 2022 | Volume: 9 | Issue: 2 | Pages: 180

10.1001/jamaoncol.2022.5511 | PMID 36416812 Get It

ImportanceProstate cancer (PCa) is marked by disparities in clinical outcomes by race, ethnicity, and age. Equitable enrollment in clinical trials is fundamental to promoting health equity.ObjectiveTo evaluate disparities in the inclusion of racial and ethnic minority groups and older adults across PCa clinical trials.Data SourcesMEDLINE, Embase, and ClinicalTrials.gov were searched to identify primary trial reports from each database's inception through February 2021. Global incidence in age subgroups and US population-based incidence in racial and ethnic subgroups were acquired from the Global Burden of Disease and Surveillance, Epidemiology, and End Results 21 incidence databases respectively.Study SelectionAll phase 2/3 randomized PCa clinical trials were eligible for age disparity analyses. Trials recruiting exclusively from the US were eligible for primary racial and ethnic disparity analyses.Data Extraction and SynthesisThis study was reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Data were pooled using a random-effects model.Main Outcomes and MeasuresEnrollment incidence ratios (EIRs), trial proportions (TPs) of participants 65 years or older or members of a racial and ethnic subgroup divided by global incidence in the corresponding age group, or US population–based incidence in the corresponding racial and ethnic subgroup, were calculated. Meta-regression was used to explore associations between trial characteristics and EIRs and trends in EIRs during the past 3 decades.ResultsOf 9552 participants among trials reporting race, 954 (10.8%) were African American/Black, 80 (1.5%) were Asian/Pacific Islander, and 8518 (78.5) were White. Of 65 US trials, 45 (69.2%) reported race and only 9 (13.8%) reported data on all 5 US racial categories. Of 286 global trials, 75 (26.2%) reported the enrollment proportion of older adults. Outcomes by race and age were reported in 2 (3.1%) and 41 (15.0%) trials, respectively. Black (EIR, 0.70; 95% CI, 0.59-0.83) and Hispanic (EIR, 0.70; 95% CI, 0.59-0.83) patients were significantly underrepresented in US trials. There was no disparity in older adult representation (TP, 21 143 [71.1%]; EIR, 1.00; 95% CI, 0.95-1.05). The representation of Black patients was lower in larger trials (meta-regression coefficient, −0.06; 95% CI, −0.10 to −0.02; P = .002).Conclusions and RelevanceThe results of this meta-analysis suggest that Black and Hispanic men are underrepresented in trials compared with their share of PCa incidence. The representation of Black patients has consistently remained low during the past 2 decades.
Incidental complex repetitive discharges on needle electromyography
Gupta, Harsh , Skolka, Michael , Laughlin, Ruple S. , Rubin, Devon I., Gupta, Harsh V , Skolka, Michael P., Skolka, Michael P

Mayo Clinic

Muscle & Nerve | November 23, 2022 | Volume: 67 | Issue: 2 | Pages: 162-165

10.1002/mus.27757 | PMID 36416248 Get It

AbstractIntroduction/AimsComplex repetitive discharges (CRDs) are spontaneous electromyography (EMG) waveforms often associated with chronic neurogenic or myopathic diseases, but incidentally identified CRDs have also been described. In this study we describe the distribution and possible significance of incidentally seen CRDs in otherwise normal electrodiagnostic studies.MethodsA retrospective chart review was performed of all patients with CRDs incidentally documented on otherwise normal electrodiagnostic studies at Mayo Clinic from January 2013 through December 2020. Each patient's clinical symptoms, referral reason, electrodiagnostic report, and imaging studies were analyzed using descriptive statistics.ResultsNinety‐four patients (86 females; mean age, 62 years; range, 20 to 86 years) and 107 CRDs were studied. The most common neuromuscular reasons for electrodiagnostic referrals included radiculopathy, peripheral neuropathy, and myopathy. Mean symptom duration was 43 months (range, 1 to 312 months). Eighty‐five patients had a CRD identified in one muscle (range, in all patients, one to five muscles). CRDs were identified most frequently in tensor fasciae latae (n = 21), biceps brachii (n = 16), and gluteus maximus (n = 9). Of the 58 patients in whom imaging was available, 46 (79%) had abnormalities that corresponded to the myotome in which the CRDs were visualized, most commonly L5 (n = 19) and C6 (n = 12). Of these 46 patients, 28 (61%) were referred for radicular or limb pain.DiscussionCRDs can be incidentally noted on otherwise normal electrodiagnostic studies, most commonly in L5 and C6 myotomes. The mechanism of CRDs in the absence of electrodiagnostic features of axon loss or remodeling is unknown.